Skip to main content
. 2019 Jun 18;23(9):6060–6071. doi: 10.1111/jcmm.14469

Figure 7.

Figure 7

EIF2A promotes cell survival during paclitaxel treatment in vivo. A, B and C, Size and weight of xenograft tumours formed by MDA‐MB‐231 derivatives including a doxycycline‐inducible shRNA targeting EIF2A and scramble shRNA. Each group was treated as indicated. Data are mean ± SEM **P < 0.01. D, Immunohistochemical analyses of the expression of EIF2A and p‐EIF2S1 in xenograft tumours as described above. E, Immunohistochemical analyses of patient samples for p‐EIF2S1 levels in patients. Top: paracentesis specimens before treatment. Bottom: surgical specimens after paclitaxel‐based neoadjuvant chemotherapy. F, Immunohistochemical analysis was graded on a scale of 1‐3 according to staining intensity. Specimens form 30 patients participated in the statistic. Paired t test was used for calculating statistical significance. G, Probability of relapse‐free survival in 3955 breast cancer patients stratified on low (black) versus high (red) expression levels of indicated genes was obtained from Kaplan‐Meier Plotter/breast cancer (http://www.kmplot.com)